- Home
- STTK vs EPM Comparison
STTK vs EPM Comparison
Compare STTK & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- EPM
- Stock Information
- Founded
- STTK 2016
- EPM 2003
- Country
- STTK United States
- EPM United States
- Employees
- STTK N/A
- EPM N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- EPM Oil & Gas Production
- Sector
- STTK Health Care
- EPM Energy
- Exchange
- STTK Nasdaq
- EPM Nasdaq
- Market Cap
- STTK 173.6M
- EPM 171.8M
- IPO Year
- STTK 2020
- EPM 1996
- Fundamental
- Price
- STTK $3.74
- EPM $5.47
- Analyst Decision
- STTK Strong Buy
- EPM Strong Buy
- Analyst Count
- STTK 3
- EPM 1
- Target Price
- STTK $10.67
- EPM $8.25
- AVG Volume (30 Days)
- STTK 129.3K
- EPM 324.6K
- Earning Date
- STTK 11-07-2024
- EPM 09-10-2024
- Dividend Yield
- STTK N/A
- EPM 8.71%
- EPS Growth
- STTK N/A
- EPM N/A
- EPS
- STTK N/A
- EPM 0.12
- Revenue
- STTK $4,123,999.00
- EPM $85,877,000.00
- Revenue This Year
- STTK $164.45
- EPM $28.11
- Revenue Next Year
- STTK N/A
- EPM N/A
- P/E Ratio
- STTK N/A
- EPM $45.92
- Revenue Growth
- STTK 380.09
- EPM N/A
- 52 Week Low
- STTK $1.33
- EPM $4.59
- 52 Week High
- STTK $11.76
- EPM $7.07
- Technical
- Relative Strength Index (RSI)
- STTK 52.85
- EPM 55.15
- Support Level
- STTK $3.60
- EPM $5.37
- Resistance Level
- STTK $3.82
- EPM $5.82
- Average True Range (ATR)
- STTK 0.23
- EPM 0.22
- MACD
- STTK 0.03
- EPM 0.07
- Stochastic Oscillator
- STTK 64.91
- EPM 71.54
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent oil and gas company operating in the US. It is engaged primarily in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas, onshore in the United States. The company's revenues are primarily generated from its crude oil, natural gas and NGL production from the Jonah Field in Sublette County, Wyoming; the Williston Basin in North Dakota; the Barnett Shale located in North Texas; the Hamilton Dome Field in Wyoming; and the Delhi Field in Northeast Louisiana. The revenue generated by the company includes royalty, mineral and working interests.